Dear NATSJ Members,
As the Japanese Society for Nucleic Acid Medicine continues the vital work of advancing antisense DNA/RNA research and fostering industry-government-academia collaboration, we're excited to share an exceptional opportunity.
TIDES Asia 2026 returns to Tokyo (February 24-26, Grand Nikko Tokyo Daiba) as Asia-Pacific's leading oligonucleotide and peptide therapeutics conference - perfectly aligned with NATSJ's mission to advance nucleic acid medicine in Japan.
Why This Event Matters for NATSJ Members:
・World-Class Japanese Science: Hear from Prof. Takeshi Wada (Tokyo University of Science) presenting breakthrough siRNA therapeutic technologies, plus leading researchers from Takeda, Chugai, and other Japanese pharmaceutical leaders
・ Asia-Pacific Focus: 80% of attendees from the Asia-Pacific region, creating unparalleled networking opportunities for Japanese researchers and industry professionals
・Comprehensive Coverage: From antisense oligonucleotides to mRNA therapeutics - spanning the entire nucleic acid medicine landscape that NATSJ champions
・Industry Collaboration: Connect with global leaders from Eli Lilly, Genentech, Novo Nordisk, and emerging Japanese biotech companies
・Regulatory Insights: Critical CMC guidance for oligonucleotide programs under accelerated review - essential for Japanese market development
Exclusive NATSJ Member Benefit:
Use discount code NATSJ10 at checkout for 10% off your registration - our way of supporting NATSJ's commitment to advancing nucleic acid medicine research and education.
This hybrid event offers both in-person networking in Tokyo and virtual access to all presentations, ensuring maximum flexibility for our members.
Register now at:
https://informaconnect.com/asia-tides/?vip_code=NATSJ10Together, let's advance the future of nucleic acid medicine in Japan and across Asia-Pacific.
Best regards,
NATSJ Leadership Team
